Unlocking the Future of Diabetes Care: Metabolic Effects Hold the Key

Anne Komé, PharmD, a Clinical Pharmacist Practitioner at the UNC School of Medicine’s Endocrinology Clinic, is at the forefront of advancing diabetes care through a deeper understanding of metabolic effects. Her work, highlighted in recent discussions on innovative diabetes management, underscores the growing emphasis on personalized approaches to metabolic health.

Komé, who holds certifications including Board Certified Pharmacotherapy Specialist (CPP) and Certified Diabetes Care and Education Specialist (CDCES), brings a multidisciplinary perspective to her role. Her educational background includes a Doctor of Pharmacy from the University of North Carolina at Chapel Hill and specialized residencies at Virginia Commonwealth University and The Ohio State University. As a Clinical Pharmacist Practitioner, she collaborates with endocrinologists to optimize treatment plans for patients with diabetes and other metabolic disorders.

Recent research published in the *Journal of the American Medical Association (JAMA)* explores how metabolic effects—such as insulin resistance, glucose variability, and hormonal imbalances—could shape future diabetes care. While the study does not explicitly cite Komé, her clinical focus aligns with its findings. The study emphasizes the need for tailored interventions that address the complex interplay of metabolic factors, such as gut microbiome interactions and inflammatory markers, which traditional therapies often overlook.

“Metabolic health is not one-size-fits-all,” Komé explained in a 2025 interview with *UNC Health News*. “By understanding how individual metabolic profiles influence disease progression, we can design more effective, patient-centered strategies. This includes leveraging advancements in pharmacogenomics and digital health tools to monitor and adjust therapies in real time.”

The study cited in the *JAMA* article highlights a shift toward precision medicine in diabetes care. For example, researchers found that patients with specific genetic variants responded better to certain classes of glucose-lowering medications, such as SGLT2 inhibitors or GLP-1 receptor agonists. Komé’s work in the Endocrinology Clinic at Eastowne reflects this trend, as she integrates pharmacogenomic data into her consultations to guide medication selection and dosing.

Complementing this research is a 2025 initiative at the University of North Carolina, where Komé and her team developed an advanced diabetes rotation for pharmacy residents. The program, detailed in a *PubMed* study, aims to enhance residents’ clinical knowledge and confidence in managing complex cases. “Our goal is to equip future pharmacists with the skills to address the metabolic nuances of diabetes,” Komé said. “This includes not only drug therapy but also lifestyle interventions and patient education.”

Despite these advancements, challenges remain. The *JAMA* study notes that metabolic research is still in its early stages, with many questions about long-term outcomes and cost-effectiveness. Additionally, disparities in access to advanced therapies and diagnostic tools persist, particularly in underserved communities. Komé acknowledges these barriers but remains optimistic. “Innovation must go hand in hand with equity,” she said. “We need policies that ensure all patients can benefit from these breakthroughs.”